HistoSonics Highlights Histotripsy Data and Trials at ASCO GI Symposium

HistoSonics has shared an update.

The company announced its participation in the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco from January 8–10, where it will host an educational dinner focused on “Histotripsy for Medical Oncology: 1-Year Outcomes, Publications & Proposed Trials.” The event will feature clinical experts from Banner MD Anderson Cancer Center and Moffitt Cancer Center, moderated by HistoSonics’ Medical Director, and the company will showcase its Edison Histotripsy System at booth 98. The post also notes that use of the Edison System outside liver applications remains limited to clinical investigations.

For investors, this update highlights HistoSonics’ efforts to deepen clinical and oncologist engagement around its histotripsy technology, particularly in gastrointestinal cancers. Presenting 1-year outcomes and proposed trials at a major oncology conference may help expand clinical evidence, support future regulatory pathways, and strengthen relationships with key opinion leaders. Increased visibility at ASCO GI could enhance the company’s positioning within the interventional oncology and noninvasive tumor ablation markets, potentially supporting longer-term commercialization prospects for the Edison System. However, current limitations to clinical investigations outside liver applications indicate that near-term revenue impact may remain modest until broader indications and approvals are secured.